Cheng-Yu Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cheng-Yu Liao has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Shi Chen
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
21 shared publications - Zu-Wei Wang
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
16 shared publications - Shun-Cang Zhu
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
15 shared publications - Yi-Feng Tian
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
15 shared publications - Cheng-Ke Xie
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
14 shared publications - Hao-Xiang Zhang
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
14 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (63) , e23468
Hypertemperature‐Detonated Biomimetic Semiconductor Stromal Bombs for Enhanced Immunotherapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by “copper avidity”, which easily leads to the dysregulation of copper ion homeostasis. It is possible to develop targeted nanodrugs that selectively kill cancer cells via cuproptosis. However, the dense stroma of PDAC acts as an airtight wall, which not only limits the penetration and distribution of therapeutic agents but also promotes immunosuppressive mechanisms via its hypoxia‐promoting effects, often leading to treatment failure. Thus, we developed a near‐infrared (NIR)‐responsive semiconductor polymer‐metal‒organic framework (MOF) nanoreactor (SPNMCH) that was loaded with copper sulfide nanoclusters (CuS x NCs) and hyaluronidase (HAase). This biomimetic semiconductor “bomb” extensively demolishes the wall (by highly activating HAase) and precisely eliminates tumor cells (through its active copper uptake to induce cuproptosis). Simultaneously, the synergistic effects of increased oxygen delivery and cuproptosis elicit robust antitumor immune responses to inhibit tumor progression and distant metastasis, and strong immune memory effects as observed in four mouse cancer models. Additionally, SPNMCH can be combined with anti‐programmed death receptor 1 (PD‐1) antibodies to further promote T cell‐mediated antitumor immunity. This study reveals a promising strategy for establishing a “hot” tumor immune niche in PDAC to promote the response to immunotherapy.
- 28 September 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (63) , e23468
Open AccessHypertemperature‐Detonated Biomimetic Semiconductor Stromal Bombs for Enhanced Immunotherapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by “copper avidity”, which easily leads to the dysregulation of copper ion homeostasis. It is possible to develop targeted nanodrugs that selectively kill cancer cells via cuproptosis. However, the dense stroma of PDAC acts as an airtight wall, which not only limits the penetration and distribution of therapeutic agents but also promotes immunosuppressive mechanisms via its hypoxia‐promoting effects, often leading to treatment failure. Thus, we developed a near‐infrared (NIR)‐responsive semiconductor polymer‐metal‒organic framework (MOF) nanoreactor (SPNMCH) that was loaded with copper sulfide nanoclusters (CuS x NCs) and hyaluronidase (HAase). This biomimetic semiconductor “bomb” extensively demolishes the wall (by highly activating HAase) and precisely eliminates tumor cells (through its active copper uptake to induce cuproptosis). Simultaneously, the synergistic effects of increased oxygen delivery and cuproptosis elicit robust antitumor immune responses to inhibit tumor progression and distant metastasis, and strong immune memory effects as observed in four mouse cancer models. Additionally, SPNMCH can be combined with anti‐programmed death receptor 1 (PD‐1) antibodies to further promote T cell‐mediated antitumor immunity. This study reveals a promising strategy for establishing a “hot” tumor immune niche in PDAC to promote the response to immunotherapy.
- Open Access
- 22 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Targeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.
- 22 November 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessTargeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Table S1 Baseline characteristics of necrosis foci in clinical PDAC samples
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Table S1 Baseline characteristics of necrosis foci in clinical PDAC samples
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S2 The identification of the necroptosis-regulating lncRNA TRAF3IP2-AS1 in PDAC
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S2 The identification of the necroptosis-regulating lncRNA TRAF3IP2-AS1 in PDAC
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S1 The cell marker for cell type definition and the flowchart of PDOX model construction.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S1 The cell marker for cell type definition and the flowchart of PDOX model construction.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S4 TRAF3IP2-AS1 deficiency-induced necroptosis promotes M2-like macrophage polarization through the release of TGFβ1
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S4 TRAF3IP2-AS1 deficiency-induced necroptosis promotes M2-like macrophage polarization through the release of TGFβ1
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S5 In co-culture with macrophages, TRAF3IP2-AS1 deficiency-induced necroptosis promotes the enhancement of EMT via the secretion of TGFβ1.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S5 In co-culture with macrophages, TRAF3IP2-AS1 deficiency-induced necroptosis promotes the enhancement of EMT via the secretion of TGFβ1.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. PDAC is characterized by prominent necrotic foci within the tumor and a high propensity for distant liver metastasis, leading to a poor prognosis. In this study, using patient-derived organoid models, single-cell RNA sequencing, and multiplex immunofluorescence staining of samples from patients with PDAC, in vivo TGFβ1 conditional knockout mouse models, and 3D in vitro models, we discovered that the formation of intratumoral necrotic foci in pancreatic cancer is closely associated with liver metastatic events. This process was triggered by the deficiency of the long noncoding RNA TRAF3IP2-AS1 that induced necroptosis, which was accompanied by an immunosuppressive microenvironment. Mechanistically, TRAF3IP2-AS1 blocked necroptosis by reducing the mRNA stability of MLKL through competitively binding to IGF2BP2. Loss of TRAF3IP2-AS1 also promoted necroptosis by promoting RIPK3 phosphorylation via interference with the ubiquitination of the phosphatase PPM1B that dephosphorylates RIPK3. Additionally, TRAF3IP2-AS1 deficiency promoted the release of TGFβ1 from tumor cells, which induced an M2-like immunosuppressive phenotype and the release of more TGFβ1. The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer.Significance:TRAF3IP2-AS1 deficiency drives necroptosis in pancreatic cancer cells to engender a prometastatic immunosuppressive niche mediated by TGFβ1 production, providing mechanistic understanding of necroptosis and therapeutic strategies for treating liver metastasis.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. PDAC is characterized by prominent necrotic foci within the tumor and a high propensity for distant liver metastasis, leading to a poor prognosis. In this study, using patient-derived organoid models, single-cell RNA sequencing, and multiplex immunofluorescence staining of samples from patients with PDAC, in vivo TGFβ1 conditional knockout mouse models, and 3D in vitro models, we discovered that the formation of intratumoral necrotic foci in pancreatic cancer is closely associated with liver metastatic events. This process was triggered by the deficiency of the long noncoding RNA TRAF3IP2-AS1 that induced necroptosis, which was accompanied by an immunosuppressive microenvironment. Mechanistically, TRAF3IP2-AS1 blocked necroptosis by reducing the mRNA stability of MLKL through competitively binding to IGF2BP2. Loss of TRAF3IP2-AS1 also promoted necroptosis by promoting RIPK3 phosphorylation via interference with the ubiquitination of the phosphatase PPM1B that dephosphorylates RIPK3. Additionally, TRAF3IP2-AS1 deficiency promoted the release of TGFβ1 from tumor cells, which induced an M2-like immunosuppressive phenotype and the release of more TGFβ1. The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer.Significance:TRAF3IP2-AS1 deficiency drives necroptosis in pancreatic cancer cells to engender a prometastatic immunosuppressive niche mediated by TGFβ1 production, providing mechanistic understanding of necroptosis and therapeutic strategies for treating liver metastasis.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S3 TRAF3IP2-AS1 deficiency leads to necroptosis in PDAC.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S3 TRAF3IP2-AS1 deficiency leads to necroptosis in PDAC.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S7 TRAF3IP2-AS1 deficiency regulates PPM1B ubiquitination through TRAF3IP2
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
Supplementary Fig. S7 TRAF3IP2-AS1 deficiency regulates PPM1B ubiquitination through TRAF3IP2